Background: Chemerin is a newly discovered adipokine that regulates adipocyte development, metabolic function as well as immune function. Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that belongs to the transforming growth factor-beta family. Aim of the study: was to evaluate the serum levels of Chemerin and AMH in one trial to show their possible involvement in the pathogenesis of PCOS and their association with obesity. Subjects and methods: This study was performed on eighty subjects divided into 4 groups: Group I: 20 nonobese control (BMI< 30), Group II: 20 non-obese patient with polycystic ovarian syndrome (BMI< 30), Group III: 20 obese Control (BMI ≥ 30) and Group IV: 20 obese patient with PCOS (BMI ≥ 30). Serum levels of Chemerin and AMH were estimated by ELISA. Results: Results showed a significant increase in serum levels of Chemerin and AMH in (non-obese and obese) PCOS groups when compared to their controls. Results showed also a significant increase in the serum level of Chemerin in obese PCOS group when compared to non-obese PCOS group. While a significant decrease in serum level of AMH in obese PCOS group when compared to non-obese PCOS group. There were a significant positive correlation between Chemerin and AMH in PCOS groups. Conclusion: Chemerin together with AMH may be used as a biomarker for early detection of PCO and Clinical parameters as Infertility and Hyper and rogenism in women with PCOS.

No abstract

Background: Hyperemesis gravidarum is a condition that affects pregnant women (HG),serum levels of human chorionic gonadotropin (hCG) and estradiol are increased than in pregnant women who are not influenced. Aim of the work:To learn moreabout how elevated human chorionic gonadotropin levels and estradiol affect the intensity of hyper emesis gravidarum during the first trimester.

Background: Polycystic ovary syndrome (PCOS) is a metabolic syndrome, characterized by anovulation, hyperandrogenism and polycystic ovary. PCOS exists commonly among women at reproductive age with an incidence rate of 6-10%.Objective: To study thyroiditis as a risk factor in Polycystic Syndrome Patients. Patients and Methods:This study was a cross sectional, observation study, this study included all consecutive PCOS patients with thyroiditis visiting the outpatient clinics of the Departments of Obstetrics and Gynecology Dar El-Shefa Damnhour Hospital, carried out on 60 patients divided into two groups: Group (A): 30 PCOS patients (Case group) and Group (B): (30) Non-PCOS patients (Control group). Between December 2019 to December 2020.Results: Thyroid hormone in PCO group was significantly higher than non PCO group, also the Thyroglobulin antibody and Anti-thyroid peroxidase was significantly higher in PCO group more than non PCO. The Luteinizing hormone, Follicle stimulating hormone and Luteinizing hormone/ Follicle stimulating hormone ratio show insignificant difference between the two studied groups. The hormonal assay including estradiol, progesterone and free testosterone showed a significant increase in PCO patients more than non PCO group. The fasting blood sugar, HOMA Insulin resistance, lipid profile showed a significant increase in PCO group more than non PCO group. Regarding thyroid abnormalities, it was found that there was an increasing in goiter, overt hypothyroid, autoimmune thyroiditis and Graves disease in PCO group more than non PCO. Conclusion:Thyroiditis considered a risk factor in polycystic syndrome patients and increase the symptoms of PCOs. Patients with thyroid peroxidase and thyroglobulin autoantibodies are likely to develop thyroid dysfunction later in life.